Pharmacogenomic testing for neuropsychiatric drugs: Current status of drug labeling, guidelines for using genetic information, and test options

Pharmacotherapy

Volumn 34, Issue 2, 2014, Pages 166-184

  Drozda, Katarzyna ^a   Müller, Daniel J ^b   Bishop, Jeffrey R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Pharmacogenetics Research Clinic Neurogenetics Section Department of Psychiatry   (Canada)

Author keywords

Antidepressants; Antipsychotics; CYP2C19; CYP2D6; Pharmacogenetic testing; Pharmacogenetics; Pharmacogenomics; Stevens Johnson syndrome

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; CARBAMAZEPINE; CITALOPRAM; CLOBAZAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DESIPRAMINE; DEXTROMETHORPHAN PLUS QUINIDINE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FLUVOXAMINE; GALANTAMINE; HLA B ANTIGEN; IMIPRAMINE; MODAFINIL; NEUROPSYCHIATRIC DRUG; NORTRIPTYLINE; PHENYTOIN; PIMOZIDE; PROTRIPTYLINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROIC ACID; CENTRAL NERVOUS SYSTEM AGENTS;

AKATHISIA; ANXIETY DISORDER; AREA UNDER THE CURVE; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; CONFUSION; CYP2C19 GENE; CYP2D6 GENE; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG LABELING; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENETIC ANALYZER; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOTE; HLA B GENE; HUMAN; HUNTINGTON CHOREA; INSOMNIA; LOADING DRUG DOSE; MACULOPAPULAR RASH; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; OBSESSIVE COMPULSIVE DISORDER; PARKINSONISM; PHARMACOGENOMICS; PLASMA CONCENTRATION-TIME CURVE; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PSYCHOPATHY; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; SUICIDE; TARDIVE DYSKINESIA; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; DRUG INTERACTION; PHARMACOGENETICS; PROCEDURES;

CENTRAL NERVOUS SYSTEM AGENTS; DRUG INTERACTIONS; DRUG LABELING; GENETIC TESTING; HUMANS; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC; PSYCHOTROPIC DRUGS;

EID: 84898047653     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1398     Document Type: Review

References (73)

1. Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther 2007;6: 807-16.
2. FDA. Table of Pharmacogenomic Biomarkers in Drug Labels. Available from http://wwwfdagov/drugs/scienceresearch/researchareas/pharmacogenetics/ ucm083378htm. Accessed March 6, 2013.
3. Malhotra AK, Zhang JP, Lencz T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry 2012;8: 760-9.
4. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 2008;6: 1130-44.
5. Pirmohamed M. Pharmacogenetics: past, present and future. Drug Discov Today 2011;20: 852-61.
6. Angst J. Effect of antidepressives and genetic factors. Arzneimittelforschung 1964;14(suppl): 496-500.
7. Pare CM, Mack JW. Differentiation of two genetically specific types of depression by the response to antidepressant drugs. J Med Genet 1971;3: 306-9.
8. Pare CM, Rees L, Sainsbury MJ. Differentiation of two genetically specific types of depression by the response to antidepressants. Lancet 1962;7270: 1340-3.
9. Alexanderson B, Evans DA, Sjoqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 1969;5686: 764-8.
10. O'Reilly RL, Bogue L, Singh SM. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry 1994;7: 467-71.
11. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of Debrisoquine in man. Lancet 1977;8038: 584-6.
12. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011;1: 9-37.
13. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007;3: 247-57.
14. Schosser A, Serretti A, Souery D, et al. European Group for the Study of Resistant Depression (GSRD)-where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol 2012;7: 453-68.
15. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressantinduced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry 2001;6: 539-44.
16. Muller DJ, Schulze TG, Knapp M, et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001;5: 375-9.
17. Gebhardt S, Theisen FM, Haberhausen M, et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther 2010;2: 207-11.
18. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;3: 173-92.
19. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006;1: 75-85.
20. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 2007;9: 819-25.
21. Thorn CF, Klein TE, Altman RB. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics 2010;11: 501-5.
22. Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011;3: 464-7.
23. FDA. FDA Approved Drug Products. Available from http:// wwwaccessdatafdagov/scripts/cder/drugsatfda/. Accessed November 14, 2013.
24. Hicks JK, Swen JJ, Thorn CF, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013;5: 402-8.
25. Kirchheiner J, Rodriguez-Antona C. Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders. CNS Drugs 2009;3: 181-91.
26. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007;6: 737-48.
27. Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013;94: 324-8.
28. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011;Database issue:D913-19.
29. Yang CW, Hung SI, Juo CG, et al. HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepineinduced Stevens-Johnson syndrome. J Allergy Clin Immunol 2007;4: 870-7.
30. Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012;6: 757-65.
31. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;2: 542-6.
32. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;24: 1600-7.
33. Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010;3: 349-56.
34. Cheung YK, Cheng SH, Chan EJ, Lo SV, Ng MH, Kwan P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 2013;7: 1307-14.
35. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther 2011;5: 662-73.
36. Reich J. The effect of Axis II disorders on the outcome of treatment of anxiety and unipolar depressive disorders: a review. J Pers Disord 2003;5: 387-405.
37. Brandl EJ, Muller DJ, Richter MA. Pharmacogenetics of obsessive- compulsive disorders. Pharmacogenomics 2012;1: 71-81.
38. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;5: 442-73.
39. Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics 2013;10: 535-48.
40. GENDEP Investigators; MARS Investigators; STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genomewide pharmacogenetic studies. Am J Psychiatry 2013;2: 207-17.
41. Testai FD, Gorelick PB. Inherited metabolic disorders and stroke part 2: homocystinuria, organic acidurias, and urea cycle disorders. Arch Neurol 2010;2: 148-53.
42. Dealberto MJ. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. Int Clin Psychopharmacol 2007;6: 330-7.
43. Bezinover D, Postula M, Donahue K, Bentzen B, McInerney J, Janicki PK. Perioperative exacerbation of valproic acid-associated hyperammonemia: a clinical and genetic analysis. Anesth Analg 2011;4: 858-61.
44. Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 2012;7: 1487-504.
45. Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord 2013;2: 210-15.
46. FDA. Roche AmpliChip cytochrome P450 genotyping test and affymetrix GeneChip microarray instrumentation system. Silver Spring, MD: FDA, 2004. Available from http://www.fda. gov/MedicalDevices/ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm078879. htm. Accessed June 6, 2013.
47. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41: 815-50.
48. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009; 12: 761-804.
49. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 2009; 11: 689-723.
50. McLellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997;3: 187-91.
51. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;1: 441-6.
52. Hresko A, Haga S. Insurance coverage policies for personalized medicine. J Pers Med 2012;2: 201-16.
53. AssureRx (GeneSightRx). GeneSight Psychotropic. Avaliable from http://assurexhealth.com/products/. Accessed July 6, 2013.
54. Genelex (You Script). Pharmacogenetic Testing. Available from http://youscript.com/healthcare-professionals/what-is-youscript/ pharmacogenetic-testing/. Accessed July 6, 2013.
55. Genomas (HILOmet PhyzioType System). HILOmet Phyzio- Type System. Available from http://www.genomas.net/lph/cyp.php. Accessed July 6,2013.
56. Matrix Genomics. Drug Reponse Panel: Cytochrome P 450 Enzymes 2C19-2D6-2C9-3A5. Available from http://www.matrix genomics.com/Drug-Panel-2C19- 2D6-2C9-3A5.php. Accessed July 6, 2013.
57. LUMINEX xTAG CYP2D6. Clinical Diagnostics. Available from www.luminexcorp.com. Accessed July 6, 2013.
58. Mayo Clinic. Cytochrome P450 (CYP450) Tests. Available from http://www.mayoclinic.com/health/cyp450-test/MY00135. Accessed July 6, 2013.
59. 23andMe. Get to Know You. Available from https://www.23andme.com/. Accessed July 6, 2013.
60. Quest Diagnostics. Cytochrome P450. Available from http://www. questdiagnostics.com/testcenter/TestDetail.action?ntc=10490. Accessed July 6, 2013.
61. Laboratory Corporation of America. Cytochrome AmpliChip P450 2D6/2C19 Genotyping and Phenotyping Assay. Available from https://www.labcorp.com. Accessed July 6, 2013.
62. Genomind. The Science Behind the Genecept Assay. Available from http://www.genomind.com/products/science-behind-thetest. Accessed July 6, 2013.
63. PGxl. CYP2D6. Available from http://www.pgxlab.com/cyp- 2d6/. Accessed July 6, 2013.
64. PGxl. CYP2C19. Available from http://www.pgxlab.com/cyp- 2c19/. Accessed July 6, 2013.
65. MyGene. CYP2C19 and CYP2D6 Assays and Screening Systems. Available from http://www.promega.com/resources/pubhub/cellnotes/p450-glo-cyp2c19-and-cyp2d6- assays-and-screeningsystems- the-method-of-choice-for-p450-assays/. Accessed July 6, 2013.
66. ARUP Laboratories. ARUP Genetics Test Menu. Available from http://www.aruplab.com/genetics/tests. Accessed July 6, 2013.
67. The AmpliChip CYP 450 Test. AmpliChip CYP450 Test. Available from http://molecular.roche.com/assays/Pages/Ampli- ChipCYP450Test.aspx. Accessed July 6, 2013.
68. INFINITI (AutoGenomics). INFINITI CYP2C19. Available from http://www.autogenomics.com/pharma-2C19Plus.php. Accessed July 6, 2013.
69. INFINITI (AutoGenomics). INFINITI CYP450 2D6I. Available from http://www.autogenomics.com/pharma-2D6.php. Accessed July 6, 2013.
70. DMET Plus (Affymetrix). DMET Plus Solution. Available from http://www.affymetrix.com. Accessed July 6, 2013.
71. VeraCode ADME Core Panel (Illumina). VeraCode ADME Core Panel. Available from http://support.illumina.com/array/array- kits/veracode-adme-core-panel. ilmn. Accessed July 6, 2013.
72. iPlex ADME PGx Panel (Sequenom). iPLEX ADME PGx panel. Available from http://vantage.vanderbilt.edu/files/3213/5602/2757/Sequenom20ADME-Flyer.pdf. Accessed July 6, 2013.
73. eSensor (GenMark Diagnostics, Inc). eSensor 2C19 Genotyping Test. Available from http://www.genmarkdx.com. Accessed July 6, 2013.